Search results for " Ovarian"

showing 7 items of 137 documents

Peritoneal carcinomatosis index as a predictor of diaphragmatic involvement in stage III and IV ovarian cancer

2018

Antoni Llueca,1–3 Anna Serra,1–3 José Luis Herraiz,2 Isabel Rivadulla,1,4 Luis Gomez-Quiles,1,4 Juan Gilabert-Estelles,5,6 Javier Escrig1,3,4On behalf of the MUAPOS (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery) working group 1Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellón, Castellón, Spain; 2Department of Obstetrics and Gynecology, University General Hospital of Castellón, Castellón, Spain; 3Department of Medicine, Universitat Jaume I, Castellón, Spain; 4Department of General Surgery, University General Hospital of Castell&…

medicine.medical_specialtyperitoneal cancer indexdiaphragmatic involvementDiaphragmatic breathingcarcinomatosisOncoTargets and Therapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMedicinePeritoneal Carcinomatosis IndexPharmacology (medical)Stage (cooking)CàncerSurvival rateOriginal ResearchAdvanced ovarian canceradvanced ovarian cancerbusiness.industryupper abdominal surgerymedicine.diseaseSurgeryOncology030220 oncology & carcinogenesisConventional PCIPeritoneal Cancer IndexbusinessOvarian cancerOncoTargets and therapy
researchProduct

EMAS position statement: Predictors of premature and early natural menopause.

2019

Simoncini, Tommaso/0000-0002-2971-0079; Chung, Hsin-Fang/0000-0003-3261-5942; Mishra, Gita/0000-0001-9610-5904 WOS:000468709100014 PubMed ID: 31027683 Introduction: While the associations of genetic, reproductive and environmental factors with the timing of natural menopause have been extensively investigated, few epidemiological studies have specifically examined their association with premature (< 40 years) or early natural menopause (40-45 years). Aim: The aim of this position statement is to provide evidence on the predictors of premature and early natural menopause, as well as recommendations for the management of premature and early menopause and future research. Materials and methods…

medicine.medical_treatmentMenopause PrematureTwinsPremature ovarian insufficiencyOVARIAN DEVELOPMENT0302 clinical medicine3123 Gynaecology and paediatricsPregnancyRisk FactorsEpidemiology030212 general & internal medicineFamily historyAetiology030219 obstetrics & reproductive medicineObstetricsEstrogen Replacement TherapySmokingObstetrics and Gynecology3. Good healthEarly menopauseMenopauseParityMenarcheFemaleUnderweightmedicine.symptomMenopausemedicine.medical_specialtyPremature ovarian insufficiencyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAGEThinnessmedicineHumansPrematureMenarchePregnancyLIFE-COURSEbusiness.industryREPRODUCTIVE PERIODBody Weightmedicine.diseaseCOGNITIVE FUNCTIONBIRTH-WEIGHTAetiology; Early menopause; Premature ovarian insufficiency; Risk factors; Body Weight; Estrogen Replacement Therapy; Female; Humans; Menarche; Pregnancy; Risk Factors; Smoking; Thinness; Twins; Menopause; Menopause Premature; ParityBODY-MASS INDEXRisk factorsRISK-FACTORSHormone therapyCIGARETTE-SMOKINGbusinessSOCIOECONOMIC POSITIONMaturitas
researchProduct

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)

2020

ObjectiveTo investigate whether neoadjuvant chemotherapy followed by interval debulking surgery is superior to primary debulking surgery in terms of perioperative complications and progression-free survival, in advanced epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high tumor load.MethodsPatients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (stage IIIC-IV) underwent laparoscopy. Patients with high tumor load assessed by a standardized laparoscopic predictive index were randomly assigned (1:1 ratio) to undergo either primary debulking surgery followed by adjuvant chemotherapy (arm A), or neoadjuvant chemotherapy followed by int…

operativemedicine.medical_specialtymedicine.medical_treatmentPopulationlaw.inventionperitoneal neoplasm03 medical and health sciences0302 clinical medicineRandomized controlled triallawperitoneal neoplasmspostoperative complicationsMedicineEpithelial ovarian cancerpostoperative complication030212 general & internal medicineStage (cooking)educationLaparoscopyChemotherapyeducation.field_of_studymedicine.diagnostic_testbusiness.industryObstetrics and GynecologyGeneral MedicinePerioperativeepithelial ovarian cancer.medicine.diseaseDebulkingsurgical proceduresSurgerysurgical procedureovarian cancerSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisbusinessOvarian cancerFallopian tube
researchProduct

Rescue of ovarian function: stem cells and regenerative factors

2022

El envejecimiento y otras condiciones de daño adquiridas, como los tratamientos oncológicos, conducen a un deterioro de la función ovárica. Sin embargo, incluso cuando los ovarios dañados pierden su capacidad de ovular, permanece un conjunto residual de folículos quiescentes que podrían ser rescatados y desarrollados en un nicho ovárico adecuado, dando lugar a ovocitos maduros. Los factores solubles secretados por las células madre podrían proporcionar un entorno ovárico adecuado para mantener y promover el crecimiento folicular. Por lo tanto, la presente tesis doctoral tuvo como objetivo evaluar los efectos regenerativos de diferentes fuentes de factores secretados por células madre en mod…

ovarian agingstem cellsfemale infertilityUNESCO::CIENCIAS MÉDICASfertility rescuesoluble factorsimpaired ovarian function
researchProduct

Trasplante autólogo de médula ósea en ovario en mujeres con baja reserva ovárica y fallo ovárico precoz, para rejuvenecimiento del nicho ovárico y fa…

2020

Como consecuencia del retraso de la maternidad a causa de las tendencias sociales actuales, existe una disminución de la calidad y cantidad de ovocitos disponibles. Al problema fisiológico de la edad materna avanzada, se suman dos patologías, que asocian una baja reserva ovárica, en pacientes jóvenes: baja respuesta ovárica (del inglés, poor ovarian response, o POR), e insuficiencia ovárica prematura(del inglés, premature ovarian insufficiency o POI). Numerosos protocolos de estimulación ovárica han sido desarrollados, sin ser efectivos, siendo en la mayoría de los casos, la única opción para estas pacientes la donación de ovocitos/embriones. Varios trabajos de investigación han descrito la…

premature ovarian insufficiencycélulas madrepoor ovarian responsefactores solublesUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::Ginecologíafolículos antralesgcsf:CIENCIAS MÉDICAS ::Ciencias clínicas::Ginecología [UNESCO]reserva ováricahormona antimülleriana
researchProduct

CISTOADENOMA GIGANTE DELL'OVAIO: CONSIDERAZIONI CLINICHE E STRATEGIA DIAGNOSTICA

2004

gli autori riortano il caso di una donna obesa affetta da cistoadenoma mucinoso gigante dell'ovaio. nonostante la presenza di una massa addominale voluminosa, la paziente non accusava sintomatologia degna di rilievo.

the authors report a case of an adult fat woman presenting giant cystadenoma of the ovary. she was asymptomatics for a long time and thepresence of a giant ovarian cyst was masked by obesity.
researchProduct